|By PR Newswire||
|April 27, 2014 07:59 PM EDT||
DUBLIN, April 28, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/nm24hh/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering.
The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market.
The report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month.
The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS.
According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Geographical Segmentation
08. Buying Criteria
09. Rate of Incidence and Prevalence
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Late Stage Pipeline Snapshot
18. Key Vendor Analysis
19. Other Reports in this Series
- Covis Pharmaceutical Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline plc
- Mitsubishi Tanabe Pharma Corp.
For more information visit http://www.researchandmarkets.com/research/nm24hh/global
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Jul. 31, 2016 12:45 AM EDT Reads: 2,041
Jul. 30, 2016 11:30 PM EDT Reads: 1,337
Jul. 30, 2016 10:30 PM EDT Reads: 1,944
Jul. 30, 2016 09:45 PM EDT Reads: 1,320
Jul. 30, 2016 09:45 PM EDT Reads: 1,497
Jul. 30, 2016 09:30 PM EDT Reads: 1,533
Jul. 30, 2016 07:30 PM EDT Reads: 1,768
Jul. 30, 2016 07:30 PM EDT Reads: 1,318
Jul. 30, 2016 07:00 PM EDT Reads: 2,777
Jul. 30, 2016 05:00 PM EDT Reads: 1,311
Jul. 30, 2016 04:30 PM EDT Reads: 2,283
Jul. 30, 2016 04:30 PM EDT Reads: 586
Jul. 30, 2016 04:30 PM EDT Reads: 1,128
Jul. 30, 2016 04:15 PM EDT Reads: 660
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Jul. 30, 2016 02:30 PM EDT Reads: 1,080